Chemotherapy as adjuvant treatment for early stage endometrial cancer with high intermediate risk factors
International Journal of Gynecological Cancer Aug 31, 2018
Gao M, et al. - Researchers investigated the role of chemotherapy as adjuvant treatment for early-stage endometrial cancer (EC) with high-intermediate-risk (HIR) factors. In this prospective study, they enrolled 96 patients with early-stage EC with HIR factors, and among these, 50 patients received 3 cycles of platinum-based chemotherapy after surgery. Chemotherapy was identified as a feasible and safe adjuvant treatment for these patients. For reducing the risk of recurrence, 3 cycles of platinum-based chemotherapy were noted to be sufficient.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries